ArticleEBioMedicine2026
A preS2 aa1-26-specific humoural response marks functional cure in chronic HBV infection.
Article in EBioMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFunctional cure (FC) of chronic hepatitis B (CHB) is closely associated with restoration of HBV-specific humoural immunity, yet the epitope-resolved features of humoural immunity recovery during interferon-induced FC remain unknown.
methodsWe profiled HBV-specific humoural responses in 65 patients with CHB drawn from three independent PEG-IFNα-treated cohorts, including nucleos(t)ide analogue-treated patients with viral suppression and inactive HBsAg carriers. Linear epitope mapping was performed using phage immunoprecipitation sequencing (PhIP-seq), with key findings validated by longitudinal ELISA and complemented by ex vivo phenotypic characterisation of epitope-specific B cells using fluorescent peptide tetramers.
findingsPhIP-seq identified 297 reactive peptides, with a marked enrichment of antibody reactivity toward the HBsAg preS domain in patients who achieved FC. Longitudinal analysis demonstrated that preS2-directed antibodies, particularly those targeting the N-terminal amino acids 1-26 (preS2 aa1-26), increased progressively and closely parallelled HBsAb seroconversion, consistently distinguishing FC from non-FC group. In parallel, ex vivo B-cell profiling revealed that preS2 aa1-26-specific B cells exhibited a plasmablast-skewed and IgG-dominant profile, in contrast to the more IgM-biased and less differentiated phenotypes observed in preS1- and SHBs-specific B cells. Within the preS2-specific compartment, FC showed higher CXCR5 and CD69 expression than non-FC group, indicative of enhanced maturation and improved follicular homing potential.
interpretationPreS2 aa1-26 may serve as a key humoural HBV-specific epitope associated with functional cure, with potential implications for immunotherapeutic strategies in CHB.
fundingThis work was supported by the National Science and Technology Major Project (2025ZD01905905), National Key Research and Development Program of China (2022YFA1303600 and 2023YFC2308100), and the National Natural Science Foundation of China (82130019 and 82272311).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.